TY - JOUR
T1 - The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas
AU - Makohon-Moore, Alvin P.
AU - Lipson, Evan J.
AU - Hooper, Jody E.
AU - Zucker, Amanda
AU - Hong, Jungeui
AU - Bielski, Craig M.
AU - Hayashi, Akimasa
AU - Tokheim, Collin
AU - Baez, Priscilla
AU - Kappagantula, Rajya
AU - Kohutek, Zachary
AU - Makarov, Vladimir
AU - Riaz, Nadeem
AU - Postow, Michael A.
AU - Chapman, Paul B.
AU - Karchin, Rachel
AU - Socci, Nicholas D.
AU - Solit, David B.
AU - Chan, Timothy A.
AU - Taylor, Barry S.
AU - Topalian, Suzanne L.
AU - Iacobuzio-Donahue, Christine A.
N1 - Funding Information:
The authors thank the patients and families who generously participated in this study. They thank Richard White for critical comments on the article, and Annamalai Kumar (MSKCC) for assisting with HLA genotyping. This study was supported by the Melanoma Research Alliance (to E.J. Lipson, C.A. Iacobuzio-Donahue, and S.L. Topalian), the Bloomberg-Kimmel Institute for Cancer Immunotherapy (to E.J. Lipson and S.L. Topalian), the Barney Family Foundation (to E.J. Lipson and S.L. Topalian), Moving for Melanoma of Delaware (to E.J. Lipson and S.L. Topalian), the Laverna Hahn Charitable Trust (to E.J. Lipson and S.L. Topalian), the NCI (R01 CA142779, to S.L. Topalian), and the MSKCC TROT fellowship (T32 CA160001-06 and K99 CA229979 to A.P. Makohon-Moore). The Legacy Gift Rapid Autopsy Program at Johns Hopkins is supported by an NIH Cancer Clinical Core Support grant P30 CA006973 and a grant from the Sol Goldman Pancreatic Research Center. This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. The authors also acknowledge funding sources, including Pershing Square Sohn Cancer Research grant (to T.A. Chan), the PaineWebber Chair (to T.A. Chan), NIH R01 CA205426 (to T.A. Chan), NIH R35 CA232097 (to T.A. Chan), and the STARR Cancer Consortium (to T.A. Chan).
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Purpose: Melanoma is a biologically heterogeneous disease composed of distinct clinicopathologic subtypes that frequently resist treatment. To explore the evolution of treatment resistance and metastasis, we used a combination of temporal and multilesional tumor sampling in conjunction with whole-exome sequencing of 110 tumors collected from 7 patients with cutaneous (n ¼ 3), uveal (n ¼ 2), and acral (n ¼ 2) melanoma subtypes. Experimental Design: Primary tumors, metastases collected longitudinally, and autopsy tissues were interrogated. All but 1 patient died because of melanoma progression. Results: For each patient, we generated phylogenies and quantified the extent of genetic diversity among tumors, specifically among putative somatic alterations affecting therapeutic resistance. Conclusions: In 4 patients who received immunotherapy, we found 1-3 putative acquired and intrinsic resistance mechanisms coexisting in the same patient, including mechanisms that were shared by all tumors within each patient, suggesting that future therapies directed at overcoming intrinsic resistance mechanisms may be broadly effective.
AB - Purpose: Melanoma is a biologically heterogeneous disease composed of distinct clinicopathologic subtypes that frequently resist treatment. To explore the evolution of treatment resistance and metastasis, we used a combination of temporal and multilesional tumor sampling in conjunction with whole-exome sequencing of 110 tumors collected from 7 patients with cutaneous (n ¼ 3), uveal (n ¼ 2), and acral (n ¼ 2) melanoma subtypes. Experimental Design: Primary tumors, metastases collected longitudinally, and autopsy tissues were interrogated. All but 1 patient died because of melanoma progression. Results: For each patient, we generated phylogenies and quantified the extent of genetic diversity among tumors, specifically among putative somatic alterations affecting therapeutic resistance. Conclusions: In 4 patients who received immunotherapy, we found 1-3 putative acquired and intrinsic resistance mechanisms coexisting in the same patient, including mechanisms that were shared by all tumors within each patient, suggesting that future therapies directed at overcoming intrinsic resistance mechanisms may be broadly effective.
UR - http://www.scopus.com/inward/record.url?scp=85102313479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102313479&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-2984
DO - 10.1158/1078-0432.CCR-20-2984
M3 - Article
C2 - 33323400
AN - SCOPUS:85102313479
SN - 1078-0432
VL - 27
SP - 1516
EP - 1525
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -